RU2718863C2 - Способы и промежуточные соединения для получения ингибитора pde10 - Google Patents

Способы и промежуточные соединения для получения ингибитора pde10 Download PDF

Info

Publication number
RU2718863C2
RU2718863C2 RU2016146118A RU2016146118A RU2718863C2 RU 2718863 C2 RU2718863 C2 RU 2718863C2 RU 2016146118 A RU2016146118 A RU 2016146118A RU 2016146118 A RU2016146118 A RU 2016146118A RU 2718863 C2 RU2718863 C2 RU 2718863C2
Authority
RU
Russia
Prior art keywords
paragraphs
compound
formula
acid
source
Prior art date
Application number
RU2016146118A
Other languages
English (en)
Russian (ru)
Other versions
RU2016146118A3 (show.php
RU2016146118A (ru
Inventor
Нил С. КАТШЕЛЛ
Дженнифер Линн ГЕЙДЖ
Томас Л. ЛИТТЛ
Вэйн Дуглас ЛЬЮК
Элизабет К.А. БРОТ
Марко ДЖОНАС
Майкл Джеймс МАКДЕРМОТТ
Карл И. РЕИНЕКЕ
Original Assignee
Омерос Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Омерос Корпорейшн filed Critical Омерос Корпорейшн
Publication of RU2016146118A publication Critical patent/RU2016146118A/ru
Publication of RU2016146118A3 publication Critical patent/RU2016146118A3/ru
Application granted granted Critical
Publication of RU2718863C2 publication Critical patent/RU2718863C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/121,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00Compounds containing elements of Groups 1 or 11 of the Periodic Table
    • C07F1/02Lithium compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F19/00Metal compounds according to more than one of main groups C07F1/00 - C07F17/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F3/00Compounds containing elements of Groups 2 or 12 of the Periodic Table
    • C07F3/02Magnesium compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Materials Engineering (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
RU2016146118A 2014-04-28 2015-04-24 Способы и промежуточные соединения для получения ингибитора pde10 RU2718863C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461985400P 2014-04-28 2014-04-28
US61/985,400 2014-04-28
PCT/US2015/027647 WO2015167969A1 (en) 2014-04-28 2015-04-24 Processes and intermediates for the preparation of a pde10 inhibitor

Publications (3)

Publication Number Publication Date
RU2016146118A RU2016146118A (ru) 2018-05-30
RU2016146118A3 RU2016146118A3 (show.php) 2018-12-24
RU2718863C2 true RU2718863C2 (ru) 2020-04-15

Family

ID=54359190

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016146118A RU2718863C2 (ru) 2014-04-28 2015-04-24 Способы и промежуточные соединения для получения ингибитора pde10

Country Status (13)

Country Link
US (2) US9650368B2 (show.php)
EP (1) EP3137462B1 (show.php)
JP (1) JP6474430B2 (show.php)
KR (1) KR102496552B1 (show.php)
CN (1) CN106459026B (show.php)
AU (1) AU2015253464B2 (show.php)
BR (1) BR112016025287B1 (show.php)
CA (1) CA2946756C (show.php)
ES (1) ES2723437T3 (show.php)
IL (1) IL248585B (show.php)
NZ (2) NZ716494A (show.php)
RU (1) RU2718863C2 (show.php)
WO (1) WO2015167969A1 (show.php)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339950B (es) * 2010-03-12 2016-06-20 Omeros Corp Inhibidores de fosfodiesterasa 10 (pde10) y composiciones y metodos relacionados.
NZ630803A (en) * 2014-04-28 2016-03-31 Omeros Corp Optically active pde10 inhibitor
JP2018535969A (ja) 2015-11-04 2018-12-06 オメロス コーポレーション Pde10阻害剤の固体状態形態

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2012143610A (ru) * 2010-03-12 2014-04-20 Омерос Корпорейшн Pde10 ингибиторы и содержащие их композиции и способы

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK178590D0 (da) 1990-07-26 1990-07-26 Novo Nordisk As 1,4-disubstituerede piperaziner
PT100905A (pt) 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
ES2192192T3 (es) 1992-12-02 2003-10-01 Pfizer Dieteres de catecol como inhibidores selectivos de pde iv.
DE4323192A1 (de) 1993-07-10 1995-01-12 Basf Ag Verfahren zur Herstellung von Homo- und Copolymerisaten von Alk-1-enen
DE4325846C1 (de) 1993-07-31 1995-01-19 Herberts Gmbh Verwendung von Furan-modifizierten aromatischen Pinakolderivaten als Initiatoren und Furan-modifizierte aromatische Pinakolderivate als solche
DE4343286A1 (de) 1993-12-17 1995-06-22 Hoechst Ag Heteroaromatische Verbindungen und ihre Verwendung in flüssigkristallinen Mischungen
DE4409501A1 (de) 1994-03-19 1995-09-21 Didier Werke Ag Verschleißfutter eines Schachtofens und Stein hierfür
WO1996000218A1 (en) 1994-06-24 1996-01-04 Euro-Celtique, S.A. Compounds for and method of inhibiting phosphodiesterase iv
US5789434A (en) 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
TW424087B (en) 1995-04-06 2001-03-01 Janssen Pharmaceutica Nv 1,3-dihydro-1-(phenylalkenyl)-2H-imidazol-2-one derivatives
TW332201B (en) 1995-04-06 1998-05-21 Janssen Pharmaceutica Nv 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives
US6037370A (en) 1995-06-08 2000-03-14 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
DE69712042T2 (de) 1996-01-22 2002-10-02 Fujisawa Pharmaceutical Co., Ltd. Thiazolylbenzofuranderivate und pharmazeutische zusammensetzungen die sie enthalten
AU4015497A (en) 1996-08-26 1998-03-19 Byk Gulden Lomberg Chemische Fabrik Gmbh Thiazole derivatives useful as selective inhibitors of pde-iv
JPH1087543A (ja) 1996-09-17 1998-04-07 Chisso Corp アルコキシベンゼン誘導体、液晶組成物および液晶表示素子
US6548490B1 (en) 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
WO1999045914A1 (en) 1998-03-13 1999-09-16 Maruho Kabushikikaisha Alkyl amine derivative and local anesthetic agent using the same
GB9807354D0 (en) 1998-04-07 1998-06-03 Glaxo Group Ltd Antiviral compound
SE9804212D0 (sv) 1998-12-04 1998-12-04 Astra Pharma Prod Compounds
HK1043127B (zh) 1999-03-12 2004-12-24 贝林格尔‧英格海姆药物公司 作为消炎剂的化合物
US7141593B1 (en) 1999-06-04 2006-11-28 Abbott Laboratories Pharmaceutical formulations
GB9929552D0 (en) 1999-12-14 2000-02-09 Proteus Molecular Design Compounds
US6933304B2 (en) 2000-06-15 2005-08-23 Pharmacia Corporation Heteroarylalkanoic acids as integrin receptor antagonists
US20030032579A1 (en) 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
PL367091A1 (en) 2001-05-22 2005-02-21 Pfizer Products Inc. Crystal forms of azithromycin
US20050165185A1 (en) * 2002-04-18 2005-07-28 Spivey Alan C. Preparation of a conjugated molecule and materials for use therein
US6821502B2 (en) 2002-06-12 2004-11-23 Chevron U.S.A. Inc. Method of making aluminum-containing zeolite with IFR structure
AU2003254481A1 (en) 2002-07-27 2004-02-16 Astrazeneca Ab Chemical compounds
JP4628789B2 (ja) 2002-10-08 2011-02-09 ザ スクリプス リサーチ インスティテュート 脂肪酸アミド加水分解酵素の阻害剤
JP2006509832A (ja) 2002-10-30 2006-03-23 ニューロ3デー サイクリックヌクレオチドホスホジエステラーゼ阻害剤、その調製及び使用
TW200410921A (en) 2002-11-25 2004-07-01 Hoffmann La Roche Mandelic acid derivatives
JP4464280B2 (ja) 2002-12-06 2010-05-19 興和株式会社 エリスロポエチン産生促進剤
CA2507699A1 (en) 2002-12-20 2004-07-15 Pharmacia Corporation Heteroarylalkanoic acids as integrin receptor antagonists
WO2004071509A1 (ja) 2003-02-12 2004-08-26 Nippon Chemiphar Co., Ltd. オリゴデンドロサイト分化促進剤
AU2004232973A1 (en) 2003-04-18 2004-11-04 Memory Pharmaceuticals Corporation Pyrazole derivatives as phosphodiesterase 4 inhibitors
AR047541A1 (es) 2004-02-13 2006-01-25 Sandoz Ag Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas
CN1946703A (zh) 2004-04-20 2007-04-11 特兰斯泰克制药公司 取代的噻唑和嘧啶衍生物作为黑素细胞皮质激素受体调节剂
WO2005110410A2 (en) * 2004-05-14 2005-11-24 Abbott Laboratories Kinase inhibitors as therapeutic agents
US7351833B2 (en) 2004-07-23 2008-04-01 Abbott Laboratories (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate
US7449486B2 (en) * 2004-10-19 2008-11-11 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof
US8436176B2 (en) 2004-12-30 2013-05-07 Medicis Pharmaceutical Corporation Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
RS51385B (sr) 2005-01-07 2011-02-28 Pfizer Products Inc. Heteroaromatična jedinjenja hinolina i njihova upotreba kao pde10 inhibitora
CN101384183B (zh) 2005-02-04 2012-07-04 西诺米克斯公司 包含连接有杂芳基部分的化合物及其作为用于食物组合物的新型鲜味调节剂、促味剂和味觉增强剂的应用
EP1871770A1 (en) 2005-04-22 2008-01-02 Kalypsys, Inc. Ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders
UA91546C2 (uk) 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
MY152185A (en) 2005-06-10 2014-08-29 Novartis Ag Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
CA2617788A1 (en) 2005-08-04 2007-02-15 Apogee Biotechnology Corporation Sphingosine kinase inhibitors and methods of their use
ES2375841T3 (es) 2005-08-29 2012-03-06 Sanofi-Aventis U.S. Llc Nueva forma cristalina de un derivado de piridazino[4,5-b]indol.
US7642246B2 (en) 2005-09-13 2010-01-05 Sicor Inc. Pure rocuronium bromide
KR101439557B1 (ko) 2005-11-15 2014-09-11 오츠카 세이야쿠 가부시키가이샤 옥사졸 화합물 및 제약 조성물
JP2009521429A (ja) 2005-12-23 2009-06-04 アストラゼネカ・アクチエボラーグ Gaba−b受容体モジュレーターとしてのイミダゾール
US20090176829A1 (en) 2006-05-02 2009-07-09 Pfizer Inc Bicyclic heteroaryl compounds as pde10 inhibitors
US20080090834A1 (en) 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
CA2662535A1 (en) 2006-09-08 2008-03-13 Ore Pharmaceuticals Inc. Method for reducing or alleviating inflammation in the digestive tract
WO2008039431A2 (en) 2006-09-25 2008-04-03 Ptc Therapeutics, Inc. Crystalline forms of 3-[5-(2-fhjorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid
CN101528212A (zh) 2006-09-28 2009-09-09 默克公司 Hdac抑制剂和可螯合的金属化合物的药物组合物以及金属-hdac抑制剂螯合物
US20090253918A1 (en) 2006-10-02 2009-10-08 Janssen Pharmaceuticals, N.V. Novel intermediate for glyt1 inhibitor
US7837978B2 (en) 2006-10-13 2010-11-23 Chevron U.S.A. Inc. Process for preparing aluminum-containing molecular sieve SSZ-26
US7786139B2 (en) * 2006-11-21 2010-08-31 Omeros Corporation PDE10 inhibitors and related compositions and methods
WO2008064342A2 (en) * 2006-11-21 2008-05-29 Omeros Corporation Pde10 inhibitors and related compositions and methods
PE20081506A1 (es) 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
WO2009008906A2 (en) 2007-02-06 2009-01-15 The Trustees Of The University Of Pennsylvania Therapeutic compounds for blocking dna synthesis of pox viruses
EP2160394A1 (en) 2007-05-22 2010-03-10 Ultimorphix Technologies B.v. Tenofovir disoproxil hemi-fumaric acid co-crystal
EP2017264A1 (de) 2007-07-16 2009-01-21 Bayer Cropscience Ag Substituierte Phenylpropargylverbindungen, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren
US20090186014A1 (en) 2007-10-10 2009-07-23 Ore Pharmaceuticals Inc. Method for treatment of pancreatitis
TW200944520A (en) 2008-01-29 2009-11-01 Glaxo Group Ltd Spiro compounds as NPY Y5 receptor antagonists
WO2009143178A2 (en) 2008-05-20 2009-11-26 Omeros Corporation Pde10 inhibitors and related compositions and methods
TWI501965B (zh) 2008-06-20 2015-10-01 Lundbeck & Co As H 作為pde10a酵素抑制劑之新穎苯基咪唑衍生物
US8377930B2 (en) 2008-08-05 2013-02-19 Omeros Corporation PDE10 inhibitors and related compositions and methods
NZ630803A (en) * 2014-04-28 2016-03-31 Omeros Corp Optically active pde10 inhibitor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2012143610A (ru) * 2010-03-12 2014-04-20 Омерос Корпорейшн Pde10 ингибиторы и содержащие их композиции и способы

Also Published As

Publication number Publication date
US9650368B2 (en) 2017-05-16
WO2015167969A1 (en) 2015-11-05
US20180057484A1 (en) 2018-03-01
EP3137462B1 (en) 2019-01-30
US20160024069A1 (en) 2016-01-28
RU2016146118A3 (show.php) 2018-12-24
ES2723437T3 (es) 2019-08-27
IL248585A0 (en) 2016-12-29
EP3137462A4 (en) 2017-12-27
CN106459026A (zh) 2017-02-22
JP6474430B2 (ja) 2019-02-27
NZ630810A (en) 2016-03-31
CA2946756C (en) 2022-03-29
BR112016025287B1 (pt) 2022-10-11
RU2016146118A (ru) 2018-05-30
BR112016025287A2 (pt) 2017-08-15
AU2015253464A1 (en) 2016-10-27
KR102496552B1 (ko) 2023-02-06
KR20160147275A (ko) 2016-12-22
NZ716494A (en) 2017-07-28
EP3137462A1 (en) 2017-03-08
AU2015253464B2 (en) 2018-11-22
CN106459026B (zh) 2019-07-05
IL248585B (en) 2020-03-31
CA2946756A1 (en) 2015-11-05
JP2017513885A (ja) 2017-06-01

Similar Documents

Publication Publication Date Title
ES2557465T3 (es) Moduladores de la actividad de HEC 1 y procedimientos para ello
KR20130129180A (ko) 아미노벤조일벤조푸란 유도체의 제조 방법
CA3183040A1 (en) Processes for the preparation of an apoptosis-inducing agent
CA3108974A1 (en) Processes for the preparation of (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable forms thereof
KR20160097230A (ko) 바이사이클릭 알킬 화합물 및 합성
KR20170016894A (ko) 1,3-벤조디옥솔 헤테로사이클릭 화합물의 제조 방법
RU2718863C2 (ru) Способы и промежуточные соединения для получения ингибитора pde10
JP2024037802A (ja) (s)-tert-ブチル4,5-ジアミノ-5-オキソペンタノエートの調製プロセス
JP2021502376A (ja) ベンゾフラン誘導体の製造方法
JP2017513913A (ja) 光学活性なpde10阻害剤
KR20200144546A (ko) 피롤로아미노피리다지논 화합물 및 이의 중간체의 제조 방법
WO2010098496A1 (en) Process for producing tetrahydrotriazolopyridine derivative
CN104710417A (zh) 氮杂吲哚类衍生物及其合成方法
An et al. Efficient formation of C–S bond using heterocyclic thiones and arynes
Shi et al. An efficient and green synthesis of 3, 3′‐benzylidenebis (4‐hydroxy‐6‐methylpyridin‐2 (1H)‐one) derivatives through multi‐component reaction in ionic liquid
JP6067700B2 (ja) アルコール酸化触媒及びそれを用いたアルコール酸化方法
WO2008155745A2 (en) New process for the manufacture of 1h-imidazo[4,5-c]-quinoline ring systems
Zali-Boeini et al. One-step synthesis of imidazo [1, 2-a] pyridines in water
KR20170080190A (ko) 1,5-쌍극자의 [5+3] 고리화 첨가 반응을 이용한 8원 헤테로 고리 화합물의 제조 방법 및 이에 의해 제조된 8원 헤테로 고리 화합물
KR100902236B1 (ko) 펜에틸 벤조에이트 유도체 및 그의 제조방법
JPWO2005085204A1 (ja) 含窒素5員環化合物の製造方法
JP2001252569A (ja) 高分子固定化キラルジルコニウム触媒
WO2025240628A1 (en) Processes for preparing a pkc inhibitor
CN111704571A (zh) 光学活性2-芳基螺环[环戊烷-1,3’-吲哚]-3-甲醛的制备方法
NZ528405A (en) Process for the preparation of tetrasubstituted imidazole derivatives and novel crystalline structures thereof